1-7 of 7
Giovanni Abbadessa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma

Gaël S. Roth, Zuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, Séyédéh Tayébéh Ahmad Pour, Giovanni Abbadessa, Yi Yu, Benoit Busser, Patrice N. Marche, Vincent Leroy, Thomas Decaens
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (10): 2157–2165.
https://doi.org/10.1158/1535-7163.MCT-16-0602-T
Published: 02 October 2017
View article titled, Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
Open the PDF for Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751

Sudharshan Eathiraj, Brian Schwartz, Yi Yu, Michael J. Wick, Terence Hall, Feng Chai, Jasgit Sachdev, Giovanni Abbadessa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B183.
https://doi.org/10.1158/1535-7163.TARG-15-B183
Published: 01 December 2015
View article titled, Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751
Journal Articles

Abstract B151: In FGFR2 driven tumors, preclinical pharmacokinetics (PK), pharmacodynamics (PD) and efficacy translate into clinical activity of ARQ 087

Terence G. Hall, Ronald E. Savage, Brian Schwartz, Yi Yu, Yunxia Wang, Julia Kazakin, Giovanni Abbadessa, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Walid Shaib, Bassel el-Rayes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B151.
https://doi.org/10.1158/1535-7163.TARG-15-B151
Published: 01 December 2015
View article titled, Abstract B151: In FGFR2 driven tumors, preclinical pharmacokinetics (PK), pharmacodynamics (PD) and efficacy translate into clinical activity of ARQ 087
Journal Articles

Abstract B181: Association of AKT1E17K and PIK3CAH1047R mutations with efficacy of ARQ 092 in vitro, in vivo and in patients

Giovanni Abbadessa, Yi Yu, Sudharshan Eathiraj, Justin Meade, Michael J. Wick, Anthony Tolcher, Kyri Papadopoulos, Mansoor Saleh, Jasgit Sachdev, Feng Chai, Brian Schwartz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B181.
https://doi.org/10.1158/1535-7163.TARG-15-B181
Published: 01 December 2015
View article titled, Abstract B181: Association of AKT1E17K and PIK3CAH1047R mutations with efficacy of ARQ 092 in vitro, in vivo and in patients
Journal Articles

Abstract B185: ARQ 092 enhances the efficacy of paclitaxel, lapatinib, trastuzumab, trametinib, and ARQ 087 both in cancer cell lines and mouse xenograft cancer models

Yi Yu, Justin Meade, Michael J. Wick, Hall Terence, Sudhi Eathiraj, Brian Schwartz, Giovanni Abbadessa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B185.
https://doi.org/10.1158/1535-7163.TARG-15-B185
Published: 01 December 2015
View article titled, Abstract B185: ARQ 092 enhances the efficacy of paclitaxel, lapatinib, trastuzumab, trametinib, and ARQ 087 both in cancer cell lines and mouse xenograft cancer models
Journal Articles

Abstract B111: Efficacy of AKT inhibitor ARQ 092 compared with Sorafenib in a cirrhotic rat model with hepatocellular carcinoma

Gael S. Roth, Ayca Zeybek, Zusana Macek-Jilkova, Giovanni Abbadessa, Yi Yu, Patrice Marche, Vincent Leroy, Thomas Decaens
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B111.
https://doi.org/10.1158/1535-7163.TARG-15-B111
Published: 01 December 2015
View article titled, Abstract B111: Efficacy of AKT inhibitor ARQ 092 compared with Sorafenib in a cirrhotic rat model with hepatocellular carcinoma
Journal Articles

Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown

Sara Previdi, Giovanni Abbadessa, Francesca Dalò, Dennis S. France, Massimo Broggini
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 214–223.
https://doi.org/10.1158/1535-7163.MCT-11-0277
Published: 09 January 2012
View article titled, Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
Open the PDF for Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown in another window
Includes: Supplementary data